Salud financiera de hoja de balance de Ascelia Pharma

Salud financiera controles de criterios 4/6

Ascelia Pharma tiene un patrimonio de los accionistas total de SEK74.3M y una deuda total de SEK0.0, lo que sitúa su ratio deuda-patrimonio en 0%. Sus activos y pasivos totales son SEK87.1M y SEK12.7M respectivamente.

Información clave

Ratio deuda-patrimonio

kr0

Deuda

Ratio de cobertura de intereses	n/a
Efectivo	kr21.86m
Patrimonio	kr74.33m
Total pasivo	kr12.74m
Activos totales	kr87.07m

Actualizaciones recientes sobre salud financiera

Recent updates

Is Ascelia Pharma (STO:ACE) In A Good Position To Invest In Growth?

May 11

Ascelia Pharma (STO:ACE) Is In A Good Position To Deliver On Growth Plans

Aug 05

We Think Ascelia Pharma (STO:ACE) Can Afford To Drive Business Growth

Jan 24

We Think Ascelia Pharma (STO:ACE) Can Afford To Drive Business Growth

Aug 23

Companies Like Ascelia Pharma (STO:ACE) Are In A Position To Invest In Growth

May 19

Here's What Ascelia Pharma AB (publ)'s (STO:ACE) Shareholder Ownership Structure Looks Like

Mar 07

Helena Wennerström Is The Independent Director of Ascelia Pharma AB (publ) (STO:ACE) And They Just Picked Up 125% More Shares

Dec 09

We Think Ascelia Pharma (STO:ACE) Can Afford To Drive Business Growth

Nov 26

Análisis de la situación financiera

Pasivos a corto plazo: Los activos a corto plazo (SEK28.9M) de ACE superan a sus pasivos a corto plazo (SEK12.6M).

Pasivo a largo plazo: Los activos a corto plazo de ACE (SEK28.9M) superan a sus pasivos a largo plazo (SEK176.0K).

Historial y análisis de deuda-patrimonio

Nivel de deuda: ACE está libre de deudas.

Reducción de la deuda: ACE no ha tenido ninguna deuda en los últimos 5 años.

Hoja de balance

Análisis de cash runway

En el caso de las empresas que de media han sido deficitarias en el pasado, evaluamos si tienen al menos 1 año de cash runway.

Cash runway estable: ACE tiene menos de un año de cash runway basado en su flujo de caja libre actual.

Pronóstico de cash runway: ACE tiene menos de un año de cash runway si el flujo de caja libre sigue reduciéndose a tasas históricas de 29.1% cada año

Salud financiera de hoja de balance de Ascelia Pharma

Salud financiera controles de criterios 4/6

Información clave

Actualizaciones recientes sobre salud financiera

Is Ascelia Pharma (STO:ACE) In A Good Position To Invest In Growth?

Ascelia Pharma (STO:ACE) Is In A Good Position To Deliver On Growth Plans

We Think Ascelia Pharma (STO:ACE) Can Afford To Drive Business Growth

We Think Ascelia Pharma (STO:ACE) Can Afford To Drive Business Growth

Companies Like Ascelia Pharma (STO:ACE) Are In A Position To Invest In Growth

We Think Ascelia Pharma (STO:ACE) Can Afford To Drive Business Growth

Recent updates

Price target increased by 22% to kr9.75

New major risk - Revenue and earnings growth

Ascelia Pharma AB (publ) Successfully Meets Primary Endpoint with Strong Headline Results in Orvigance Phase 3 Study

Key Executive recently bought kr62k worth of stock

Price target decreased by 61% to kr8.00

New major risk - Revenue and earnings growth

Deputy CEO & Chief Commercial Officer recently bought kr170k worth of stock

Price target decreased by 7.1% to kr19.50

Ascelia Pharma AB (publ) to Report Fiscal Year 2024 Results on Feb 07, 2025

Ascelia Pharma AB (publ) Announces Re-Evaluation Required After Intra-Reader Inconsistency in Scoring of Images from Phase 3 Study SPARKLE

New major risk - Share price stability

Chief Scientific Officer recently bought kr86k worth of stock

New major risk - Revenue and earnings growth

Insufficient new directors

Is Ascelia Pharma (STO:ACE) In A Good Position To Invest In Growth?

Independent Director recently bought kr352k worth of stock

Ascelia Pharma AB (publ) Announces 71 Patients Have Completed the SPARKLE Study

Ascelia Pharma AB (Publ) Announces 65 Patients Completes the Sparkle Study

Price target decreased to kr48.00

Key Executive recently bought kr225k worth of stock

Ascelia Pharma AB (Publ) Announces New Data Show That the Pivotal Phase 3 Clinical Sparkle Study

Price target decreased to kr59.00

Ascelia Pharma AB Announces That the Nomination Committee in Preparation for the Annual General Meeting on 4 May 2023 Has Been Appointed

Ascelia Pharma Presents Results of Orviglance Food Effect Study At RSNA 2022 Showing Strong Liver Enhancement Both with Light Meal and in Fasting Condition

Ascelia Pharma AB (publ) to Report First Half, 2023 Results on Aug 18, 2023

Ascelia Pharma AB (Publ) Announces Resignation of Carl Bjartmar as CMO

Ascelia Pharma AB (publ) Announces Successful Final Results from Orviglance Hepatic Impairment Study

Ascelia Pharma (STO:ACE) Is In A Good Position To Deliver On Growth Plans

Ascelia Pharma AB (publ) Announces Change of CFO

Chief Commercial Officer recently bought kr310k worth of stock

Key Executive recently bought kr101k worth of stock

Chief Executive Officer recently bought kr459k worth of stock

Ascelia Pharma's Food Effect Study Shows Orviglance Image Enhancement of the Liver Is Not Reduced by Light Meal

Price target increased to kr64.00

Insufficient new directors

Ascelia Pharma Suspends Clinical Activities in Russia

Key Executive recently bought kr116k worth of stock

We Think Ascelia Pharma (STO:ACE) Can Afford To Drive Business Growth

Ascelia Pharma AB (publ) Receives FDA Acceptance of IND Application for Oncoral Clinical Trial

Ascelia Pharma AB (publ) Announces Results from Orviglance comparison study to gadolinium presented at RSNA 2021

Chief Commercial Officer recently bought kr208k worth of stock

Chief Medical Officer recently bought kr260k worth of stock

We Think Ascelia Pharma (STO:ACE) Can Afford To Drive Business Growth

Ascelia Pharma AB (publ) Announces Abstract for Orviglance Comparison Study to Gadolinium Accepted At the Radiology Conference RSNA

Ascelia Pharma AB (publ) Receives Conditional U.S. Food and Drug Administration Acceptance for Orviglance

Chief Executive Officer recently bought kr379k worth of stock

Companies Like Ascelia Pharma (STO:ACE) Are In A Position To Invest In Growth

Chief Executive Officer recently sold kr5.8m worth of stock

Chief Executive Officer exercised options to buy kr11m worth of stock.

Here's What Ascelia Pharma AB (publ)'s (STO:ACE) Shareholder Ownership Structure Looks Like

Chief Medical Officer recently bought kr392k worth of stock

Ascelia Pharma AB (publ) Presents Clinical Development Plan for Oncoral as a Novel Chemotherapy

Ascelia Pharma Gets US Patent for Second Generation Mangoral

Helena Wennerström Is The Independent Director of Ascelia Pharma AB (publ) (STO:ACE) And They Just Picked Up 125% More Shares

Independent Director recently bought kr469k worth of stock

Ascelia Pharma AB (Publ) Announces New Study Shows Mangoral's Lesion Visualization as Effective as Gadolinium Contrast Agent

New 90-day high: kr47.55

We Think Ascelia Pharma (STO:ACE) Can Afford To Drive Business Growth

New 90-day high: kr43.35

Chief Financial Officer recently bought kr67k worth of stock

Chief Executive Officer recently bought kr319k worth of stock

New 90-day high - kr29.85

Chief Commercial Officer recently bought kr149k worth of stock

New 90-day high - kr26.85

Análisis de la situación financiera

Historial y análisis de deuda-patrimonio

Hoja de balance

Análisis de cash runway

Descubre empresas con salud financiera